Bayer plans to invest $2.2 billion in a new pharmaceutical manufacturing site in New Albany, Ohio, as the company expands its U.S. production capabilities and supports growing demand across its pharmaceuticals business.
The project will be located in the New Albany International Business Park and is expected to create approximately 600 high-value permanent jobs, along with roughly 1,500 construction jobs while the facility is being built.
Bayer said the investment is a central component of its long-term growth strategy and its commitment to expanding innovation, manufacturing and patient access in the United States, which represents the company’s largest pharmaceuticals market.
The $2.2 billion project builds on more than $7 billion Bayer has spent on U.S. pharmaceutical research and development and manufacturing over the past five years.
The planned New Albany campus will use a flexible, modular design combining drug substance and drug product manufacturing within the same broader site.
Bayer plans to incorporate advanced digital technologies and automation throughout the facility as it builds additional manufacturing capacity for its growing pharmaceutical portfolio.
Initial production will support medicines across oncology, cardiovascular and renal care.
The project’s first module will focus on drug substance manufacturing and is expected to become operational in 2031.
A second module dedicated to drug product manufacturing is planned to follow in 2034.
The modular approach is intended to give Bayer additional flexibility as its portfolio and manufacturing requirements evolve.
Bayer also expects the facility to strengthen the resilience of its global Product Supply network while increasing the company’s ability to manufacture medicines closer to its U.S. customer and patient base.
The New Albany facility will complement Bayer’s existing U.S. pharmaceuticals operations, including its U.S. pharmaceuticals headquarters in Whippany, New Jersey, and sites in Pittsburgh, Pennsylvania; Berkeley, California; Cambridge, Massachusetts; Research Triangle Park, North Carolina; and San Diego, California.
Bayer said the project is also intended to become part of a broader U.S.-based collaboration ecosystem connecting academic innovation with advanced pharmaceutical manufacturing expertise.
The company sees that ecosystem as a way to support the development of future-ready manufacturing processes while strengthening connections between research, innovation and commercial production.
The New Albany investment comes as Bayer seeks to expand its pharmaceuticals business in the United States, which the company identified as its fastest-growing pharmaceutical market.
The company employed approximately 88,000 people globally in fiscal 2025 and generated €45.6 billion in sales. Bayer reported €5.8 billion in research and development expenses for the year.
KEY QUOTES:
“Bayer has long seen the United States as a key manufacturing base and innovation hub. This landmark investment underscores our commitment. The new site will be home to manufacturing expertise and a skilled workforce that will strengthen our ability to deliver innovative, high-quality medicines to patients both in the United States and abroad.”
Bill Anderson, CEO of Bayer
“The United States is a key market for Bayer’s Pharmaceuticals division. This expansion is another important step to grow our pharmaceuticals business and to meet the demand of our customers and patients in the U.S., our fastest-growing pharmaceuticals market, and beyond.”
Sebastian Guth, Global Chief Operating Officer of Bayer Pharmaceuticals and President of Bayer U.S.
“The facility will be a strong strategic addition to our global Product Supply network. As we continue to invest in our existing manufacturing sites around the globe, our planned presence in Ohio will further enhance our ability to serve our markets with greater resilience and reliability.”
Holger Weintritt, Head of Product Supply at Bayer’s Pharmaceuticals Division
